You are here
SU11248 Demonstrates Early Efficacy, Safety; Placebo Patients To Switch Immediately to Drug Therapy
SU11248 is a novel, oral multi-targeted cancer therapy that combines anti-angiogenic and anti-tumor activity to simultaneously stop the blood supply to and directly attack tumor cells.
“We are encouraged by this interim data analysis and believe this is a positive step towards establishing SU11248 as an option for patients with Gleevec-resistant GIST,” said Dr. Joseph Feczko, Pfizer president of worldwide development. “Pfizer and study investigators are working together to provide SU11248 to those enrolled in the study as quickly as possible and hope this unique therapy will continue to provide meaningful clinical benefit for cancer patients.”
SU11248 also is being studied in Phase III trials as a potential treatment for renal cell carcinoma.
Source: Pfizer, Inc.